PREMATURE EJACULATION TREATMENT MARKET ANALYSIS

Premature Ejaculation Treatment Market by Drug Type (Selective Serotonin Reuptake Inhibitors (SSRIs) (Dapoxetine, and Others), Phosphodiesterase Type 5 (PDE5) Inhibitors (Zertane, and Others), Topical Anesthetics, and Others), by Route of Administration (Oral and Topical), by Dosage Form (Pills, Spray, and Others), by Distribution Channel (Hospitals, Online Pharmacies, and Retail Pharmacies), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2026

Published In : Jul 2018
Code : CMI1956
Pages :190
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Increasing strategic collaborations for development of new diagnostic tools is expected to propel the market growth

Key players in the market are involved in strategic collaborations for the development of premature ejaculation treatment drugs. For instance, in 2012, Ampio Pharmaceuticals, Inc. entered in a strategic agreement with Ethypharm S.A. for the manufacturing of Zertane, Ampio's drug indicated for the treatment of premature ejaculation. In 2013, Absorption Pharmaceuticals LLC entered into a strategic collaboration with Kaiser Permanente for initiating clinical trial to evaluate the efficacy of Promescent lidocaine spray for men with premature ejaculation (PE). Such strategic collaborations by key players for the development, manufacturing, and evaluation of novel drugs is expected to fuel the global premature ejaculation treatment market growth.

Launch of alternative treatment methods for premature ejaculation is expected to be a major factor, which can restrain the market growth. For instance, in May 2018, InnovaDerma PLC launched a device, Prolong. Prolong is a FDA approved device used in the treatment of premature ejaculation. Launches of such devices is expected to restrain growth of the global premature ejaculation treatment market